Literature DB >> 30894018

PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia.

Fabrizio Pin1,2, Leah J Novinger3, Joshua R Huot2,4, Robert A Harris5, Marion E Couch2,3,6,7, Thomas M O'Connell2,3,6,7, Andrea Bonetto1,2,3,4,6,7.   

Abstract

Cachexia is frequently accompanied by severe metabolic derangements, although the mechanisms responsible for this debilitating condition remain unclear. Pyruvate dehydrogenase kinase (PDK)4, a critical regulator of cellular energetic metabolism, was found elevated in experimental models of cancer, starvation, diabetes, and sepsis. Here we aimed to investigate the link between PDK4 and the changes in muscle size in cancer cachexia. High PDK4 and abnormal energetic metabolism were found in the skeletal muscle of colon-26 tumor hosts, as well as in mice fed a diet enriched in Pirinixic acid, previously shown to increase PDK4 levels. Viral-mediated PDK4 overexpression in myotube cultures was sufficient to promote myofiber shrinkage, consistent with enhanced protein catabolism and mitochondrial abnormalities. On the contrary, blockade of PDK4 was sufficient to restore myotube size in C2C12 cultures exposed to tumor media. Our data support, for the first time, a direct role for PDK4 in promoting cancer-associated muscle metabolic alterations and skeletal muscle atrophy.-Pin, F., Novinger, L. J., Huot, J. R., Harris, R. A., Couch, M. E., O'Connell, T. M., Bonetto, A. PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia.

Entities:  

Keywords:  C2C12 myotubes; chemotherapy; energy metabolism; mitochondria; skeletal muscle atrophy

Mesh:

Substances:

Year:  2019        PMID: 30894018      PMCID: PMC6529344          DOI: 10.1096/fj.201802799R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  64 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Physiological characterization of a mouse model of cachexia in colorectal liver metastases.

Authors:  Kate T Murphy; Adam Struk; Cathy Malcontenti-Wilson; Christopher Christophi; Gordon S Lynch
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

3.  Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation.

Authors:  Tatsuo Furuyama; Kazuko Kitayama; Hitoshi Yamashita; Nozomu Mori
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

Review 4.  Cancer cachexia: mediators, signaling, and metabolic pathways.

Authors:  Kenneth C H Fearon; David J Glass; Denis C Guttridge
Journal:  Cell Metab       Date:  2012-07-12       Impact factor: 27.287

5.  Diversity of the pyruvate dehydrogenase kinase gene family in humans.

Authors:  R Gudi; M M Bowker-Kinley; N Y Kedishvili; Y Zhao; K M Popov
Journal:  J Biol Chem       Date:  1995-12-01       Impact factor: 5.157

Review 6.  Regulation of PDH activity and isoform expression: diet and exercise.

Authors:  S J Peters
Journal:  Biochem Soc Trans       Date:  2003-12       Impact factor: 5.407

7.  The role of FOXO and PPAR transcription factors in diet-mediated inhibition of PDC activation and carbohydrate oxidation during exercise in humans and the role of pharmacological activation of PDC in overriding these changes.

Authors:  Dumitru Constantin-Teodosiu; Despina Constantin; Francis Stephens; David Laithwaite; Paul L Greenhaff
Journal:  Diabetes       Date:  2012-02-07       Impact factor: 9.461

8.  Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways.

Authors:  Rafael Barreto; Giorgia Mandili; Frank A Witzmann; Francesco Novelli; Teresa A Zimmers; Andrea Bonetto
Journal:  Front Physiol       Date:  2016-10-19       Impact factor: 4.566

9.  Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia.

Authors:  Sarah M Judge; Chia-Ling Wu; Adam W Beharry; Brandon M Roberts; Leonardo F Ferreira; Susan C Kandarian; Andrew R Judge
Journal:  BMC Cancer       Date:  2014-12-24       Impact factor: 4.430

10.  Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.

Authors:  Rafael Barreto; David L Waning; Hongyu Gao; Yunlong Liu; Teresa A Zimmers; Andrea Bonetto
Journal:  Oncotarget       Date:  2016-07-12
View more
  16 in total

1.  microRNA-15b-5p shuttled by mesenchymal stem cell-derived extracellular vesicles protects podocytes from diabetic nephropathy via downregulation of VEGF/PDK4 axis.

Authors:  Tiantian Zhao; Qingsong Jin; Lili Kong; Dongdong Zhang; Yaqin Teng; Liangyan Lin; Xiaoyan Yao; Yongjun Jin; Minglong Li
Journal:  J Bioenerg Biomembr       Date:  2021-11-22       Impact factor: 2.945

2.  Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia.

Authors:  Joshua R Huot; Leah J Novinger; Fabrizio Pin; Ashok Narasimhan; Teresa A Zimmers; Thomas M O'Connell; Andrea Bonetto
Journal:  JCI Insight       Date:  2020-05-07

3.  Up-regulation of TUG1 can regulate miR-494/PDK4 axis to inhibit LPS-induced acute lung injury caused by sepsis.

Authors:  Lin Yang; Li Zhao; Hui Zhang; Peili Chen
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 4.  Signaling Pathways That Control Muscle Mass.

Authors:  Anna Vainshtein; Marco Sandri
Journal:  Int J Mol Sci       Date:  2020-07-04       Impact factor: 5.923

5.  Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice.

Authors:  Alyson L Essex; Fabrizio Pin; Joshua R Huot; Lynda F Bonewald; Lilian I Plotkin; Andrea Bonetto
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-19       Impact factor: 5.555

Review 6.  The Implications of PDK1-4 on Tumor Energy Metabolism, Aggressiveness and Therapy Resistance.

Authors:  Emine Atas; Monika Oberhuber; Lukas Kenner
Journal:  Front Oncol       Date:  2020-12-15       Impact factor: 6.244

Review 7.  Mechanisms of muscle atrophy and hypertrophy: implications in health and disease.

Authors:  Roberta Sartori; Vanina Romanello; Marco Sandri
Journal:  Nat Commun       Date:  2021-01-12       Impact factor: 14.919

8.  Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways.

Authors:  Ashok Narasimhan; Xiaoling Zhong; Ernie P Au; Eugene P Ceppa; Atilla Nakeeb; Michael G House; Nicholas J Zyromski; C Max Schmidt; Katheryn N H Schloss; Daniel E I Schloss; Yunlong Liu; Guanglong Jiang; Bradley A Hancock; Milan Radovich; Joshua K Kays; Safi Shahda; Marion E Couch; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Cancers (Basel)       Date:  2021-04-20       Impact factor: 6.639

9.  Pharmacological or genetic inhibition of iNOS prevents cachexia-mediated muscle wasting and its associated metabolism defects.

Authors:  Jason Sadek; Derek T Hall; Bianca Colalillo; Amr Omer; Anne-Marie K Tremblay; Virginie Sanguin-Gendreau; William Muller; Sergio Di Marco; Marco Emilio Bianchi; Imed-Eddine Gallouzi
Journal:  EMBO Mol Med       Date:  2021-06-07       Impact factor: 12.137

Review 10.  Molecular mechanisms of cancer cachexia‑induced muscle atrophy (Review).

Authors:  Wei Yang; Jianhui Huang; Hui Wu; Yuqing Wang; Zhiyin Du; Yuanbo Ling; Weizhuo Wang; Qian Wu; Wenbin Gao
Journal:  Mol Med Rep       Date:  2020-10-16       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.